Paul Carter
Senior Director and Senior Staff Scientist, Antibody Engineering
"The long duration of drug development relative to the span of a career reminds me that, like the renown landscape gardener, Lancelot "Capability" Brown, one needs to plant for future generations."
I joined Genentech as a Postdoctoral Fellow in 1986 and left as a Senior Scientist and Head of the Postdoctoral Program in 2000. I then rejoined Genentech in 2010 as a Senior Director and Staff Scientist to lead the Antibody Engineering Department. My most significant contributions to drug development include initiating the antibody humanization program at Genentech. I am a co-inventor of 6 humanized or human antibodies that have reached clinical development, including one humanized antibody that later became a commercial product.
My lab and our collaborators developed ‘knobs-in-holes’ technology that has been widely used by many different organizations for generating bispecific antibodies and other bifunctional molecules. At Genentech, ‘knobs-in-holes’ was included in the design of a one-armed antibody and 5+ bispecific antibodies that have reached clinical trials. My lab also invented common light chain technology used by several different companies for developing 6+ bispecific antibodies that have entered clinical trials including 1 approved product. We also developed technologies for high-level expression of antibody Fab fragments that were subsequently utilized for production of an antibody drug that is now marketed.
I have authored or co-authored 110+scientific publications that together have been cited 17,000+ times. I am an inventor or co-inventor on 45+ granted US patents and 53+ published US patent applications. I have co-organized 15+ international conferences on antibody engineering and antibody therapeutics. I have delivered 110+ conference presentations and invited lectures including 11+ keynote presentations.